---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-023015"
form_type: "8-K"
ticker: "ARMP"
cik: "0000921114"
company_name: "Armata Pharmaceuticals, Inc."
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T23:03:54.969006+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Armata Pharma enters $10M secured credit agreement with Innoviva at 14% p.a., matures March 2026

## Summary
- $10 million term loan from Innoviva at 14.0% annual interest, secured by substantially all assets.
- Loan matures March 12, 2026; proceeds to fund development of phage candidates AP-PA02 and AP-SA02.
- Amendments extend maturity of three prior Innoviva credit agreements also to March 12, 2026.
- Innoviva is Armata's largest shareholder; loan guaranteed by domestic subsidiaries.
- Company pursuing additional non-dilutive funding for late-stage trials.

## SEC filing metadata
- accession: 0001104659-25-023015
- form_type: 8-K
- ticker: ARMP
- cik: 0000921114
- company_name: Armata Pharmaceuticals, Inc.
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921114/000110465925023015/0001104659-25-023015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921114/000110465925023015/tm258929d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-023015
- JSON: https://secwatch.observer/filing/0001104659-25-023015.json
- Plain text: https://secwatch.observer/filing/0001104659-25-023015.txt

## Key facts
- Debt Financings
  Armata Pharmaceuticals, Inc. incurred credit facility of $10 million with Innoviva Strategic Opportunities LLC at 14.0% per annum maturing March 12, 2026.
  - Instrument: credit facility
  - Principal: $10 million
  - Counterparty: Innoviva Strategic Opportunities LLC
  - Rate: 14.0% per annum
  - Maturity: March 12, 2026
  - Event: incurrence
  source text: The March 2025 Credit Agreement provides for a secured term loan facility in an aggregate amount of $10 million (the “Loan”) at an interest rate of 14.0% per annum, and has a maturity date of March 12, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/921114/000110465925023015/0001104659-25-023015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.